Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:01 16/01/2026 GMT			5-day change	1st Jan Change
130.00 ^EUR	+0.85%		+1.33%	+6.04%

01-16	MERCK KGAA : JP Morgan reiterates its Buy rating	ZD
01-15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE

Merck signs renewable energy contract for South Korea sites

Published on 11/04/2025 at 02:26 pm GMT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Merck KGaA

01-16	MERCK KGAA : JP Morgan reiterates its Buy rating	ZD
01-15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
01-13	Merck KGaA Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 11:15 AM
01-13	Germany's Merck receives FDA acceptance of new drug application for pimicotinib	RE
01-13	Abbisko Tumor Treatment Pimicotinib Accepted for U.S. Review	MT
01-13	Merck KGaA's New Drug Application for Tenosynovial Giant Cell Tumor Treatment Gets US FDA Nod	MT
01-13	Abbisko Therapeutics Announces FDA Acceptance of the Nda for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor	CI
01-12	MERCK KGAA : Goldman Sachs reaffirms its Buy rating	ZD
01-07	UK Regulator Approves Merck KGaA Unit's Ogsiveo for Progressing Desmoid Tumors	MT
01-07	MERCK KGAA : Barclays gives a Neutral rating	ZD
01-06	Repligen Corporation Announces Executive Changes, Effective March 13, 2026	CI
01-02	Dax and MDax: Fewer Women on Executive Boards	DP
12-23	Innovassynth Investments Limited Announces Board and Executive Change, Effective December 23, 2025	CI
12-22	AlphaValue/Baader Europe Lifts Merck KGaA PT, Affirms Buy Rating	MT
12-22	German Pharmaceutical Giant Merck Receives Approval for Tumor Drug in China	RE
12-22	Merck KGaA Announces Chinese Approval for Abbisko's TGCT Treatment	MT
12-22	Merck KGaA Announces Approval of Pimicotinib as Systemic Treatment in China for Tenosynovial Giant Cell Tumor	CI
12-19	Merck target raised after analyst change
12-19	Trump, nine pharmaceutical companies strike deal to cut prices	RE
12-18	MERCK KGAA : Gets a Buy rating from JP Morgan	ZD
12-17	AbbVie, several other pharma companies near MFN deal with Trump, sources say	RE
12-15	Immunome jumps after promising results for its desmoid tumor treatment
12-15	MERCK KGAA : JP Morgan maintains a Buy rating	ZD
12-15	Immunome reports 'knockout' late-stage study results for rare tumor drug	RE
12-11	Merck KGaA's SpringWorks Gets UK Clearance for Plexiform Neurofibromas Therapy	MT

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (42.1%); - pharmaceutical products (40%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.9%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.7%), Switzerland (1.9%), Europe (22.6%), the United States (25.7%), North America (1.3%), China (13.5%), Asia/Pacific (19.6%), Latin America (7%), Middle East and Africa (3.7%).

Employees

62,346

Sector

Pharmaceuticals

Calendar

03-05 - Q4 2025 Earnings Release

More about the company